ATOMO DIAGNOSTICS LIMITED — Capital/Financing Update 2022

Aug 21, 2022

22 August 2022

==> picture [75 x 73] intentionally omitted <==

ASX Announcement

COVID-19 RAT Supply Agreement signed with AllTest & TGA Update

SYDNEY, Australia, 22 August 2022 - Atomo Diagnostics Limited (ASX:AT1) ( Atomo ) is pleased to announce the signing of an agreement with Hangzhou AllTest Biotech Co., Ltd, ( AllTest ) for supply of a COVID-19[1] Rapid Antigen self-test in the Australian and New Zealand markets under the Atomo brand and provide a TGA Update.

• Atomo to seek to register in Australia and New Zealand as product sponsor, an Atomo branded version of AllTest’s existing TGA approved COVID-19 Rapid Antigen self-test; Australian Register of Therapeutic Goods (ARTG No): 374574. Atomo has ordered an initial quantity of current JusChek branded product due in Australia late August to enable commercial launch to commence in parallel with activities to register an Atomo branded version of the product, with registration anticipated during Q.2 FY23.

• Atomo and AllTest to continue discussions related to an expanded relationship with focus on commercialisation of blood based rapid tests in the US market, utilising Atomo’s integrated test platform, the Atomo APP and AllTest’s extensive range of commercialised rapid test assays currently being sold by AllTest in non-US markets.

Atomo’s CEO John Kelly said, “with some resurgence in COVID-19 infections in Australia and continued uncertainty related to future variants of concern, we are very pleased to be able to secure access to a well proven and low-cost Rapid Antigen self-test that will enable us to remain competitive in the local COVID self-test market”.

The company now intends to withdraw its existing submission to TGA related to the Atomo branded version of the Access Bio COVID-19 Rapid Antigen self-test and focus its commercial efforts on the AllTest product, which is categorised as “High sensitivity” by the TGA and is available at a competitive price point.

In relation to broader discussions with AllTest, Mr Kelly said “we have identified a number of test applications commercialised by AllTest that we feel are suited to home test products on an Atomo device, and are working with AllTest to assess opportunities in the US market where the COVID-19 pandemic has transformed the home test landscape”.

For more information, please contact:

John Kelly Managing Director & CEO e. john.kelly@atomodiagnostics.com p. +61 401 922 279

1 COVID-19 rapid testing detects SARS-COV-2, the virus that causes COVID-19

Level 1, 3-5 George St Leichhardt NSW 2040

Atomo Diagnostics Limited ACN 142 925 684

==> picture [75 x 73] intentionally omitted <==

This announcement was authorised by the Managing Director & CEO.

About Atomo

Atomo is an Australian headquartered medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market.

Atomo’s unique patented devices simplify testing procedures, enhance usability and improve reliability across rapid point-of-care (POC) and at-home testing applications. The Company has successfully commercialised a number of products across international markets and has supply agreements in place for testing applications targeting infectious diseases including COVID-19, HIV, viral vs bacterial differentiation and female health. See more at www.atomodiagnostics.com

Level 1, 3-5 George St Leichhardt NSW 2040

Atomo Diagnostics Limited ACN 142 925 684